Comparison of Response Rate of RCHOP Chemotherapy in Germinal Center B-cell like vs non-Germinal Center B-cell like Diffuse Large B cell non-Hodgkin Lymphoma

Irfan  Ali; Nadeem  Paracha; Sobia  Latif; Syed Saif ul Hassan; Sajid  Hussain

doi:10.51253/pafmj.v76iSUPPL-9.11663

Authors

Irfan Ali Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Nadeem Paracha Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Sobia Latif Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Syed Saif ul Hassan Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Sajid Hussain Department of Medical Oncology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-9.11663

Keywords:

Germinal Center B-Cell Like; Non-Hodgkin Lymphoma; Response; R-CHOP

Abstract

Objective: To compare response rate of RCHOP chemotherapy in patients of germinal center B-cell like vs non-germinal center B-cell like diffuse large B cell non-Hodgkin lymphoma.

Study Design: Prospective comparative study.

Place and Duration of Study: Oncology Department, Combined Military Hospital Rawalpindi, Pakistan Aug 2021 to Jul 2023.

Methodology: This study was conducted on patients who were diagnosed with diffuse large B cell non Hodgkin lymphoma at out oncology unit. Patients were divided into two Groups for the sake of comparison. Group-I had patients with germinal center B-cell like lymphoma while Group-II had patients with non-germinal center B-cell like lymphoma. Both the Groups were administered standard R-CHOP chemotherapy for six cycles after every twenty-one days. At the end of six cycles, response via Deauville score (PET scan), presence of neutropenia and mortality were compared in both the Groups.

Results: A total of ninety patients diagnosed as diffuse large B cell lymphoma were recruited for this study. Median age of the lymphoma patients included in the study was 43 (41) years. Out of total patients, 55(61.1%) were male while 35(38.9%) were female. At the end of six cycles of RCHOP chemotherapy, response was statistically significantly better in GCB patients as compared to non-GCB patients (p-value<0.001).

Conclusion: Patients suffering from germinal center B-cell like had better response on PET scan at the end of six cycles of R-CHOP chemotherapy as compared to patients managed for non-germinal center B-cell like lymphoma. Neutropenia and deaths were

Downloads

Download data is not yet available.

References

1. Hao T, Li-Talley M, Buck A, Chen W. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Sci Rep 2019; 9(1): 12070.

http://doi.org/10.1038/s41598-019-48445-1

2. Miranda-Filho A, Piñeros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol; 5(1): e14-e24. http://doi.org/10.1016/S2352-3026(17)30232-6

3. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin's Lymphoma. Med Sci 2021; 9(1): 5. http://doi.org/10.3390/medsci9010005

4. Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol 2022; 12(3): 960317. http://doi.org/10.3389/fonc.2022.960317

5. Sheikh IN, Elgehiny A, Ragoonanan D, Mahadeo KM, Nieto Y, Khazal S. Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective. Cancers 2022; 14(12): 2912. http://doi.org/10.3390/cancers14122912

6. Hübel K. Lymphoma: New Diagnosis and Current Treatment Strategies. J Clin Med 2022; 11(6): 1701.

http://doi.org/10.3390/jcm11061701

7. Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013; 381(9880): 1817-1826.

http://doi.org/10.1016/S0140-6736(13)60313-X

8. Kim J, Lee JO, Paik JH, Lee WW, Kim SE, Song YS. Different predictive values of interim 18F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma. Ann Nucl Med 2017; 31(1): 1-11.

http://doi.org/10.1007/s12149-016-1123-6

9. He XH, Li B, Yang S, Lu N, Zhang X, Zou SM, et al. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma. Chin J Cancer 2012; 31(6): 306-314.

http://doi.org/10.5732/cjc.011.10420

10. Mahmood H, Habib M, Aslam W, et al. Clinicopathological spectrum of Diffuse Large B Cell lymphoma: a study targeting population yet unexplored in Pakistan. BMC Res Notes 2021; 14(1): 354.

http://doi.org/10.1186/s13104-021-05768-5

11. Cho MC, Chung Y, Jang S, Park CJ, Chi HS, Huh J et al. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP. Medicine 2018; 97(45): e13046.

http://doi.org/10.1097/MD.0000000000013046

12. Vodicka P, Klener P, Trneny M. Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options. Onco Targets Ther 2022; 15(3): 1481-1501.

http://doi.org/10.2147/OTT.S326632

13. Shen R, Fu D, Dong L, Zhang MC, Shi Q, Shi ZY, et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. Signal Transduct Target Ther 2023; 8(1): 145.

http://doi.org/10.1038/s41392-023-01358-y

14. Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol 2021; 96(5): 617-629.

http://doi.org/10.1002/ajh.26151

15. Kurch L, Hüttmann A, Georgi TW. Interim PET in Diffuse Large B-Cell Lymphoma. J Nucl Med 2021; 62(8): 1068-1074.

http://doi.org/10.2967/jnumed.120.255034

16. Huang Y, Ye S, Cao Y, Li Z, Huang J, Huang H, et al. Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients. Sci World J 2012; 2012(1): 897178.

http://doi.org/10.1100/2012/897178

17. Xia Y, Li ZM, Shi YX, Xia ZJ, Jiang WQ, Huang HQ. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma. Ai Zheng 2009; 28(2): 146-149.

18. He XH, Li B, Yang S. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma. Chin J Cancer 2012; 31(6): 306-314.

http://doi.org/10.5732/cjc.011.10420

19. Tyagi A, Abrari A, Khurana A, Tyagi S. Immunohistochemical subtyping of diffuse large B-cell lymphoma into germinal center B-cell and activated B-cell subtype, along with correlation of the subtypes with extranodal involvement, serum lactate dehydrogenase, and positron emission tomography scan-based response assessment to chemotherapy. J Cancer Res Ther 2022; 18(4): 1129-1136.

http://doi.org/10.4103/jcrt.JCRT_842_20